This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|October 15, 2016
- BioPharm International-10-15-2016
- Volume 2016 eBook
- Issue 2
Cell Line Quality Technologies
Author(s)Susan Haigney
BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances.
Advertisement
Chinese hamster ovary (CHO) cells are a common and stable option for mammalian expression systems, but what are the other cell line options in upstream processing and how do they compare in quality and stability to CHO cells? And what are the best techniques for ensuring quality and stability in cell-line development? BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances and the analytical techniques companies can use to ensure quality and stability.
Articles in this issue
about 10 years ago
Investigation Effectiveness Drives Human Performance Excellenceabout 10 years ago
Data Integrity Challenges in Manufacturingabout 10 years ago
Evaluating Technology and Innovation in Biopharmaceutical Manufacturingabout 10 years ago
Seeking Accelerated Biosimilar Characterizationabout 10 years ago
Plant-Made Pharmaceuticals—Accelerating Drug Development Globallyabout 10 years ago
Testing the BrothAdvertisement
Related to this article
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
4
The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus
5